Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm

Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its p...

Full description

Bibliographic Details
Main Authors: Marek Z. Wojtukiewicz, Piotr Skalij, Piotr Tokajuk, Barbara Politynska, Anna M. Wojtukiewicz, Stephanie C. Tucker, Kenneth V. Honn
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/5/1144
id doaj-d1dd048f93b442dfb8437e03b82088ca
record_format Article
spelling doaj-d1dd048f93b442dfb8437e03b82088ca2020-11-25T02:02:48ZengMDPI AGCancers2072-66942020-05-01121144114410.3390/cancers12051144Direct Oral Anticoagulants in Cancer Patients. Time for a Change in ParadigmMarek Z. Wojtukiewicz0Piotr Skalij1Piotr Tokajuk2Barbara Politynska3Anna M. Wojtukiewicz4Stephanie C. Tucker5Kenneth V. Honn6Department of Oncology, Medical University of Białystok, 12 Ogrodowa St., Białystok 15-027, PolandDepartment of Oncology, Medical University of Białystok, 12 Ogrodowa St., Białystok 15-027, PolandDepartment of Oncology, Medical University of Białystok, 12 Ogrodowa St., Białystok 15-027, PolandDepartment of Philosophy and Human Psychology, Medical University of Białystok, 37 Szpitalna St., 15-295 Białystok, PolandDepartment of Philosophy and Human Psychology, Medical University of Białystok, 37 Szpitalna St., 15-295 Białystok, PolandBioactive Lipids Research Program, Department of Pathology-School of Medicine, Detroit, MI 48202, USABioactive Lipids Research Program, Department of Pathology-School of Medicine, Detroit, MI 48202, USAThrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its prevention. Direct oral anticoagulants (DOACs) are a new option for anticoagulation therapy. Recently published results of large randomized clinical trials have confirmed that DOAC may be a reasonable alternative to LMWH in cancer patients. The following review summarizes the current evidence on the safety and efficacy of DOAC in the treatment and prevention of cancer-related thrombosis. It also draws attention to the limitations of this group of drugs, knowledge of which will facilitate the selection of optimal therapy.https://www.mdpi.com/2072-6694/12/5/1144thrombosiscancertreatmentprophylaxisanticoagulantsDOAC
collection DOAJ
language English
format Article
sources DOAJ
author Marek Z. Wojtukiewicz
Piotr Skalij
Piotr Tokajuk
Barbara Politynska
Anna M. Wojtukiewicz
Stephanie C. Tucker
Kenneth V. Honn
spellingShingle Marek Z. Wojtukiewicz
Piotr Skalij
Piotr Tokajuk
Barbara Politynska
Anna M. Wojtukiewicz
Stephanie C. Tucker
Kenneth V. Honn
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
Cancers
thrombosis
cancer
treatment
prophylaxis
anticoagulants
DOAC
author_facet Marek Z. Wojtukiewicz
Piotr Skalij
Piotr Tokajuk
Barbara Politynska
Anna M. Wojtukiewicz
Stephanie C. Tucker
Kenneth V. Honn
author_sort Marek Z. Wojtukiewicz
title Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_short Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_full Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_fullStr Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_full_unstemmed Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_sort direct oral anticoagulants in cancer patients. time for a change in paradigm
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2020-05-01
description Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its prevention. Direct oral anticoagulants (DOACs) are a new option for anticoagulation therapy. Recently published results of large randomized clinical trials have confirmed that DOAC may be a reasonable alternative to LMWH in cancer patients. The following review summarizes the current evidence on the safety and efficacy of DOAC in the treatment and prevention of cancer-related thrombosis. It also draws attention to the limitations of this group of drugs, knowledge of which will facilitate the selection of optimal therapy.
topic thrombosis
cancer
treatment
prophylaxis
anticoagulants
DOAC
url https://www.mdpi.com/2072-6694/12/5/1144
work_keys_str_mv AT marekzwojtukiewicz directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT piotrskalij directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT piotrtokajuk directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT barbarapolitynska directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT annamwojtukiewicz directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT stephaniectucker directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT kennethvhonn directoralanticoagulantsincancerpatientstimeforachangeinparadigm
_version_ 1724951476862713856